DGX

Quest Diagnostics Incorporated

DGX, USA

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

https://www.questdiagnostics.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.8

Next Payout:

Jan 28, 2026

Yield:

1.7622 %
DGX
stock
DGX

What Quest Diagnostics (DGX)'s Octave MS Collaboration Means For Shareholders simplywall.st

Read more →
DGX
stock
DGX

Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward 富途牛牛

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$197.3125

Analyst Picks

Strong Buy

8

Buy

1

Hold

10

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

22.20

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

2.83

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

3.38 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.51 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

14.88 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.22

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 87.81% of the total shares of Quest Diagnostics Incorporated

1.

Vanguard Group Inc

(12.7286%)

since

2025/06/30

2.

BlackRock Inc

(9.2226%)

since

2025/06/30

3.

T. Rowe Price Associates, Inc.

(6.434%)

since

2025/06/30

4.

State Street Corp

(4.6368%)

since

2025/06/30

5.

JPMorgan Chase & Co

(3.8737%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.1382%)

since

2025/07/31

7.

Boston Partners Global Investors, Inc

(2.7184%)

since

2025/06/30

8.

Geode Capital Management, LLC

(2.6671%)

since

2025/06/30

9.

Victory Capital Management Inc.

(2.5122%)

since

2025/06/30

10.

Vanguard 500 Index Investor

(2.4699%)

since

2025/07/31

11.

Vanguard Mid Cap Index Institutional

(2.2271%)

since

2025/07/31

12.

Morgan Stanley - Brokerage Accounts

(1.9183%)

since

2025/06/30

13.

Dimensional Fund Advisors, Inc.

(1.7003%)

since

2025/06/30

14.

Victory Sycamore Established Value R

(1.6991%)

since

2025/06/30

15.

Wells Fargo & Co

(1.6423%)

since

2025/06/30

16.

Grantham, Mayo, Van Otterloo & Co., LLC

(1.5631%)

since

2025/06/30

17.

Amvescap Plc.

(1.483%)

since

2025/06/30

18.

Bank of America Corp

(1.4305%)

since

2025/06/30

19.

Wellington Management Company LLP

(1.4301%)

since

2025/06/30

20.

Fidelity 500 Index

(1.2655%)

since

2025/07/31

21.

Davis Selected Advisers

(1.2112%)

since

2025/06/30

22.

SPDR® S&P 500® ETF

(1.2087%)

since

2025/08/31

23.

iShares Core S&P 500 ETF

(1.2014%)

since

2025/08/31

24.

NORGES BANK

(1.1855%)

since

2025/06/30

25.

JPM US Equity Income-Composite

(1.156%)

since

2025/06/30

26.

JPMorgan Equity Income I

(1.156%)

since

2025/07/31

27.

JHancock Disciplined Value I

(1.1343%)

since

2025/07/31

28.

AllianceBernstein L.P.

(1.1105%)

since

2025/06/30

29.

FMR Inc

(1.1048%)

since

2025/06/30

30.

UBS Asset Mgmt Americas Inc

(1.0879%)

since

2025/06/30

31.

T. Rowe Price U.S. Value Equity Tr-D

(1.0347%)

since

2025/06/30

32.

JPMorgan Mid Cap Value L

(1.0129%)

since

2025/07/31

33.

Vanguard Windsor Investor Shares

(1.0028%)

since

2025/06/30

34.

JPM US Mid Cap Value-Composite

(0.9933%)

since

2025/06/30

35.

T. Rowe Price U.S. Large-Cap Core Tr-C

(0.9447%)

since

2025/06/30

37.

T. Rowe Price Dividend Growth

(0.93%)

since

2025/07/31

38.

Vanguard Value Index Inv

(0.8848%)

since

2025/07/31

39.

T. Rowe Price US Large-Cap Core

(0.878%)

since

2025/06/30

40.

T. Rowe Price US Large-Cap Core Eq Comp

(0.878%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(8)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(6)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.